The bacterial type 6 secretion system (T6SS) is a dynamic apparatus that translocates proteins between cells by a mechanism analogous to phage tail contraction. T6SS sheaths are cytoplasmic tubular structures composed of stable VipA-VipB (named for ClpV-interacting protein A and B) heterodimers. Here, the structure of the VipA/B sheath was exploited to generate immunogenic multivalent particles for vaccine delivery. Sheaths composed of VipB and VipA fused to an antigen of interest were purified from Vibrio cholerae or Escherichia coli and used for immunization. Sheaths displaying heterologous antigens generated better immune responses against the antigen and different IgG subclasses compared with soluble antigen alone. Moreover, antigen-specific antibodies raised against sheaths presenting Neisseria meningitidis factor H binding protein (fHbp) antigen were functional in a serum bactericidal assay. Our results demonstrate that multivalent nanoparticles based on the T6SS sheath represent a versatile scaffold for vaccine applications.
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vaccine delivery | type 6 secretion system | nanoparticles | antigen | immunogen T he bacterial type 6 secretion system (T6SS) is a dynamic apparatus that translocates proteins between effector cells and target cells (1) (2) (3) (4) . It is conserved in 25% of Gram-negative bacteria, including Vibrio cholerae, Pseudomonas aeruginosa and Escherichia coli. The T6SS plays a crucial role in bacterial pathogenicity and symbiosis, targeting either eukaryotic cells or competitor bacterial cells (5) . The assembled and functional T6SS apparatus has structural homology to bacteriophage T4 phage tail components and can be divided into two distinct assemblies: a contractile phage tail-like structure and a transmembrane complex (6) . V. cholerae VipA and VipB (named for ClpV-interacting protein A and B) and orthologous proteins in other bacteria build within the cytosol of effector cells a tubular sheath structure that is anchored to the various layers of the cell envelope through its association with the T6SS transmembrane complex (7) .
VipA/B sheaths are composed of six protofilaments arranged as a right-handed six-start helix similar to early T4 tail sheaths (8) . Each protofilament is formed by a VipA/B heterodimer, and the atomic-resolution structure of a native contracted V. cholerae sheath has been recently determined by cryo-electron microscopy (9) . Stable expression of VipB in V. cholerae requires the presence of VipA, and VipA/B heterodimers can be recruited into assembled tubular sheath structures spontaneously (10, 11) . Because both ends of VipA are exposed on the external surface of the sheath tubules, a C-terminal fusion of VipA protein with superfolded green fluorescent protein (sfGFP) is functional in T6SS sheath assembly and activity, as previously demonstrated (3) .
Because these tubular structures are assembled in cytoplasm and can be purified from bacteria (3), we explored the possibility that T6SS sheaths could be used as a new particle-based delivery system for vaccine antigens. It is thought that particulate structures used for vaccine formulations are efficiently targeted for uptake by antigenpresenting cells (APCs) and interact directly with antigen-specific B cells generating humoral responses (12) . Although particulate protein antigens may be more resistant to degradation, they are eventually proteolytically processed, and the resulting peptides are presented by the major histocompatibility complex (MHC) class I and class II molecules in a process that leads to activation of
CD4
+ and CD8 + T-cell helper and effector responses. Examples of particulate vaccine delivery systems include lipid-based systems [emulsions, immune-stimulating complexes (ISCOMs), liposomes, virosomes], polymer-based structures (e.g., nano-/ microparticles), and virus-like particles (VLPs), with each of these systems presenting their own spectrum of advantages and disadvantages for practical use as human immunogens (13) .
In this work, VipA/B sheaths displaying heterologous protein antigens on the surface were generated and tested as a particulate vaccine antigen delivery system. Our results show that sheath-like structures displaying different antigens were immunogenic and that antibodies elicited against one of these, the Neisseria meningitidis factor H binding protein (fHbp), were functional in a serum bactericidal assay. The T6SS antigen delivery system demonstrates potential as a multivalent particle to deliver one or more antigens simultaneously into the same antigen-presenting cell. Moreover, the use of heterologous VipA and VipB sheaths displaying a common antigen in sequential vaccine booster regimens minimizes immune responses against the delivery system itself and focuses the immune responses against the common antigen of interest.
Results

Generation of Sheath-Like Structures Exposing sfGFP on the Surface.
A recombinant Duet vector system was used to enable assembly of sheath structures made by VipA, VipB, and multiple VipA fusions (see SI Materials and Methods for details). One copy of vipB and two copies of vipA DNA constructs were generated to express VipB, VipA with a C-terminal 6xHis tag (VipAhis), and a second VipA fusion protein displaying sfGFP as a C-terminal
Significance
Critical aspects that limit use of nanoparticles as vaccine delivery systems include the technical difficulty of preparing particles under conditions that allow controlled protein loading and folding. Biologic nanoparticles offer advantages over chemically derived particles that require harsh organic solvents for preparation. Here, we demonstrate that the multimeric sheath structure of the bacterial type 6 secretion system (T6SS) can be exploited to generate particles that display on their surface many copies of specific proteins of interest. T6SS sheaths represent a functional vaccine delivery system with remarkable flexibility due to the ability to biochemically modify these structures to expand or enhance potential immunogenicity.
extension. Sheath-like structures were purified from either V. cholerae 2740-80 or E. coli BL21-DE3 strains, using a two-step protocol. The first step applies ultracentrifugation to collect larger particulate sheath structures, and the second step uses Ni-affinity chromatography to purify proteins associated with VipAhis (Fig.  1A) . Purified sheaths from either V. cholerae or E. coli were analyzed by negative staining using electron microscopy (EM). EM analysis showed that purified sheaths are organized into 40-to 200-nm tubular structures (Fig. 1B) with an appearance that corresponded to contracted sheaths (3). Thus, VipA and VipB can autoassemble in tubular structures in the E. coli cytoplasm without the need for other T6SS components not expressed in this bacterial strain. Furthermore, sheaths were tested for the ability to autoassemble in cell-free in vitro conditions. To this end, recombinant VipAhis, VipBhis, and VipA-sfGFPhis were purified under denaturing conditions in the presence of urea, mixed, and allowed to refold. Tubular structures similar to typical sheaths were detected by EM analysis (Fig. S1 ). Surface sfGFP exposure on sheath particles was determined by immunogold staining with anti-GFP antibodies and Protein A-gold particles (Fig. 1C) . These results indicate exposure of sfGFP on the surface and the inclusion of VipA-sfGFP fusion protein in each assembled sheath.
Interaction of Sheath Nanoparticles with Phagocytic Eukaryotic Cells.
Because the size of purified sheath structures is comparable with other particles that can be engulfed by antigen presenting cells (APCs) (14, 15) , we explored their interaction with phagocytic eukaryotic cells. Sheath-like structures exposing sfGFP (sfGFP sheaths) purified from V. cholerae or E. coli were incubated with RAW264-7 macrophages as an in vitro model for antigen uptake. Compared with a negative control, after 6 h of incubation, GFPpositive RAW264-7 macrophages were detected, indicating that sheaths purified from V. cholerae or E. coli are taken up or associated to the surface of macrophages ( Fig. 2A) . The number of positive RAW264-7 cells also increased over time ( Fig. 2A) . Confocal microscopy was used to determine localization of sheaths inside of the eukaryotic cells (Fig. 2B) . Z-stack analysis showed the presence of sfGFP sheaths, on cell surface and inside the cells. These experiments demonstrated that sheath-like structures interact with macrophages and therefore are likely to interact with other APCs in the context of immunization protocols.
Immunogenicity of Sheaths and Induction of an Immune Response
Against the Exposed Heterologous Antigen sfGFP. Mice were immunized with sfGFP sheaths as a proof-of-concept experiment to determine whether a heterologous protein exposed on sheaths was more immunogenic compared with the soluble recombinant protein alone. Groups of five BALB/c female mice were immunized three times biweekly with sfGFP sheaths purified from V. cholerae or E. coli with or without alum as an adjuvant. In addition, two groups of mice were immunized with "empty sheaths" from V. cholerae or E. coli (i.e., formed only with VipA and VipB) mixed with sfGFP recombinant protein to determine whether sheaths have adjuvant properties for "bystander antigens" that were not tightly associated with the particles. These experiments showed that sfGFP sheaths were immunogenic and elicited a strong humoral immune response against sfGFP (Fig. 3A) . No significant differences in total IgG ELISA titers were observed against sfGFP when exposed on a sheath's surface or as a recombinant protein in combination with empty sheaths. In both cases, titers were similar or slightly higher compared with recombinant sfGFP alone.
Because there was no significant difference between sheaths isolated from the two host systems in terms of sheath structure/ composition and immune response, E. coli was chosen as the preferred host strain for sheath assembly and purification because it is (i) a common host for recombinant protein expression and (ii) amenable to scale-up processes that meet good manufacturing guidelines. To dissect the features of the immune response induced by sheaths purified from E. coli, IgG subclass repertoires were determined by ELISA (Fig. 3B) . IgG1 antibodies were the most represented IgG, reflecting results obtained measuring total IgG and correlating with the use of alum (16) . Interestingly, levels of IgG2a and IgG2b were significantly higher when immunization was done with VipA/B/A-sfGFP compared with a recombinant sfGFP alone or in combination with empty VipA/B sheaths.
Furthermore, we tested the feasibility to incorporate multiple proteins in a single nanoparticle structure by coexpressing two fusion proteins, VipA-sfGFP and VipA-mCherry, together with VipAhis and VipB. Although the system requires optimization, our results showed that tubular structures containing both fusion proteins were assembled and were able to induce an immune response against both sfGFP and mCherry (Fig. S2) .
Use of Heterologous VipA-VipB Sheaths to Boost a Focused Immune
Response Against a Common Displayed Antigen. We explored the immunogenicity of heterologous VipA-VipB sheaths displaying the same antigen decoration (sfGFP) and tested whether boosting drove the immune response selectively against the common antigen and not the scaffold proteins. VipA and vipB genes from P. aeruginosa or Acinetobacter baylyi were used to express VipAhis, VipB, and VipA-sfGFP in E. coli. Resulting sheaths were analyzed by Coomassie blue staining and EM ( Fig. S3 A and B) . P. aeruginosa proteins produced homogeneous and relatively long sheaths whereas sheaths produced from A. baylyi proteins were shorter and less uniform. Flow cytometry confirmed that both sheath preparations interacted with RAW264-7 cells and that a higher percentage of GFP-positive cells was observed after incubation with A. baylyi sheaths compared with P. aeruginosa (Fig. S3C ). Sheath preparations were used to immunize two groups of mice. The first group was immunized with sfGFP sheaths made by V. cholerae VipA/B sequences as a reference condition. The second group was immunized with sfGFP sheaths prepared with V. cholerae VipA/B for the first injection, P. aeruginosa sfGFP-VipA/B for the second injection, and A. baylyi sfGFP-VipA/B for the third injection. Sera were collected 1 wk postimmunization, and ELISA was performed to detect antibodies against V. cholerae VipA and VipB (used as reference) and sfGFP. As shown in Fig. 3C , an immune response against sfGFP was developed in both immunization groups. In contrast, antibody titers against V. cholerae VipA and VipB were significantly lower for the group immunized with the three different sheath preparations, suggesting that the immune response was focused on the common displayed sfGFP antigen rather than conserved epitopes that exist between the VipA and VipB proteins present in these heterologous sheaths. The initial boost with V. cholerae sfGFP-VipA/B sheaths resulted in higher antibody response than boosting with P. aeruginosa sfGFP-VipA/B sheaths, suggesting that stimulation of VipA/VipB-specific CD4 T cells may provide B-cell help for the induction of sfGFP antibodies.
Use of Sheaths to Deliver Neisseria meningitidis fHbp Antigen. To test the feasibility of using sheaths as a delivery system for more complex proteins, Neisseria meningitidis group B antigen factor H binding protein (fHbp) was used. The fHbp lipoprotein is a surface-exposed molecule characterized by a beta-barrel at its C terminus (17) , and it is currently a part of two recently licensed vaccines against meningococcal B disease (18, 19) . The N terminus of fHbp was fused to the C terminus of V. cholerae VipA and expressed in E. coli together with VipAhis and VipB. Results show fully assembled sheaths in the presence of fHbp fusion protein (Fig. S4 A and B) . Sheaths and recombinant fHbp were used for immunization experiments, with alum as an adjuvant. As a further control, one group of mice was also immunized with empty VipA/B sheaths mixed with recombinant fHbp protein.
Total IgG ELISA titers showed that fHbp sheaths were immunogenic, with antibody levels comparable with the recombinant antigen alone (Fig. 4A) . Interestingly, sheaths with incorporated fHbp induced significantly higher immune response compared with recombinant fHbp mixed with VipA/B sheaths. IgG1 titers reflected the results obtained measuring total IgGs, as observed for sfGFP sheaths. In the case of IgG2a and IgG2b, although the differences were not statistically significant, fHbp sheaths induced generally higher levels of antigen-specific antibodies, compared with other soluble immunogens (Fig. S4C) .
The functionality of antibodies raised against fHbp alone or exposed on the surface of sheaths was tested by serum bactericidal assay (SBA), which is currently used as an immunological correlate of protection for meningococcal vaccines (20) . Increasing concentrations of sera were incubated with N. meningitidis clinical isolate NZ98/254 in the presence of an active baby rabbit complement. Bacterial colony-forming units (cfu) corresponding to viable bacteria were counted after 1 h of incubation. The results showed similar SBA titers for sera obtained from mice immunized with fHbp sheaths, with or without alum as adjuvant, and higher titers than sera obtained using recombinant protein alone or mixed with empty VipA/B sheaths (Fig. 4B) . These results suggest that the different IgG subclasses elicited by sheath particles were more functional in binding to the antigen on the N. meningitidis surface, fixing complement, and causing bacterial killing.
Modification of Sheath Surface by SrtA-Mediated Ligation. To broaden the T6SS sheath platform for antigen delivery, we developed a system that enables antigen fusion on preassembled, purified sheaths. Sortases are membrane-associated transpeptidases that anchor proteins to the cell wall in Gram-positive bacteria (21) and have recently been exploited to label a variety of proteins at the C terminus, N terminus, or internal regions (22) . To apply sortase technology to the T6SS sheath system, appropriately tagged proteins were engineered to be substrates for sortase. First, VipA was modified at its C terminus to contain the LPETGG sortase-recognition motif of Staphylococcus aureus sortase A (SrtA), and VipA-sort/ VipB sheaths were purified from E. coli. Secondly, 6X-his-SUMO-(Gly) 5 -tagged versions of sfGFP, mCherry, and fHbp were generated and purified as recombinant proteins (Fig. 5) . SUMO protease was used to cleave the SUMO tag, allowing release of (Gly) 5 -sfGFP (Fig.  5, lane 5) . When mixed with the VipA-sort/VipB sheaths, (Gly) 5 sfGFP was recognized by a recombinant SrtA and ligated to the LPETGG motif exposed on the external surface of sheaths (Fig. 5,  lane 6 ). After 10 min of incubation with SrtA, an extra band (∼45 kDa) corresponding to the predicted molecular mass of the VipA-sfGFP fusion protein was observed. This band was confirmed as VipA-sfGFP by Western blot analysis (Fig. S5A) . The SrtA reaction was also performed by ligating either (Gly) 5 -sfGFP and (Gly) 5 mCherry to the same reaction mixture, generating sheaths decorated with both sfGFP and mCherry in equimolar amounts (Fig. 5, lane  11) . Similar results were obtained using (Gly) 5 -fHbp, demonstrating the versatility of the reaction (Fig. S5 B and C) .
Discussion
Despite decades of effort, there remains significant interest in development of new vaccine delivery systems that efficiently elicit a protective immune response against pathogens and cancer, particularly in multivalent formats (13) . Recently, attention has been focused on nanoparticles where the vaccine antigen is either encapsulated within the particles (i.e., liposome, ISCOMs, and polymeric nanoparticles) or decorated on the surface of particles (i.e., virus-like particles and nondegradable nanoparticles). In general, these particle-based approaches are thought to improve the immunogenicity of antigens by increasing the influx of professional APCs into the injection site, promoting antigen uptake by APCs and protecting antigens from early degradation. Critical aspects that limit use of these vaccine delivery systems include the technical feasibility of consistent particle preparation at reasonable yields, protein antigen stability during manufacture, and the toxicity associated with components present in some particle formulations.
We hypothesized the structure of T6SS VipA/B sheaths could be exploited to generate biologically derived, multivalent particles as a nanoparticle delivery system for vaccine antigens. This study confirmed the predicted utility. T6SS sheaths can be easily purified from E. coli bacterial cell lysates in a two-step protocol to generate particulate structure with size ranging from 40 to 200 nm, optimal for uptake by APCs (23) . Sheath particles were immunogenic with increased representation of IgG isotypes compared with soluble protein antigens. Even in the absence of adjuvant, induction of antigen-specific IgGs demonstrated functionality in a serum bactericidal assay; this result suggests that different isotype classes have different functionality despite recognizing the same antigen with The repertoire of IgG subclasses in sera was measured by ELISA for mice immunized with sfGFP sheaths from E. coli. Titers are reported as absorbency units at OD 405 for serum dilutions (dil.): dil. 1:32,000 for total IgG and IgG1; dil. 1:4,000 for IgG2a, IgG2b, and IgG3. (C) Mice were immunized with either (i) three rounds of sfGFP sheaths containing V. cholerae VipA/VipB or (ii) sequential injections of sfGFP sheaths containing V. cholerae VipA/VipB, P. aeruginosa VipA/VipB, or A. baylyi VipA/VipB. Sera were collected after each immunization (P1, post-1; P2, post-2; P3 post-3) and tested by ELISA to determine specific antibodies against sfGFP, V. cholerae VipA, and V. cholerae VipB. *P value < 0.05; **P value < 0.01; ***P value < 0.001; ****P value < 0.0001; ns, not statistically significant. If not specified, there was no statistical difference between samples. different affinities. The particulate nature of T6SS sheaths is likely responsible for induction of a Th1-derived response, as proposed elsewhere (13) . It will be interesting to dissect the immune response induced by sheath particles and determine the role of proinflammatory pathways (i.e., the stimulation of NLRP3 inflammasome) in the process. We expected sheaths to have adjuvant properties, but our results showed that mixing recombinant protein with empty sheaths did not result in a significant increase in immune response against the antigen. Thus, antigen fusion to VipA is critical to expose the protein with correct folding on the sheath surface to present immunogen to the immune system in a multivalent fashion similar to what happens when antigens are displayed on pathogen surfaces. In addition, sheath structures may enhance immune responses by retaining antigen at the site of injection and reducing the rate of degradation. Although such "depotting" can also be achieved by conjugating the antigen to gold or silica particles, our system has the advantage of preventing toxicity associated with the use of nondegradable material.
Another key advantage of T6SS sheaths as a delivery system is the potential for these structures to incorporate multiple proteins in a single nanoparticle and deliver them simultaneously into the same APC, as we demonstrated using two VipA fusion proteins, VipA-sfGFP and VipA-mCherry. Alternatively, sheaths may allow assembly of recombinant proteins separately purified under denaturing conditions. The advantage of this approach is that a variety of different VipA fusion proteins can in theory be expressed and purified separately in an unfolded state, mixed in optimal ratios based on their inherent immunogenicity, and assembled into multivalent sheath particles after refolding in vitro.
In contrast with chemically defined nanoparticle structures, one drawback of biologic-based vaccine delivery platforms is the likelihood that an immune response will be generated against the delivery system itself, potentially limiting use of the delivery platform to a single dose. Thus, a platform that minimizes this predicted antisystem response would be highly desirable. We took advantage of the presence of T6SS in many Gram-negative bacteria and, by using heterologous VipA-VipB pairs during boosting, we showed a focused immune response to the common displayed antigen target (i.e., sfGFP). This feature is potentially advantageous when selection of functional or high affinity antibodies is required in an application, as shown for HIV and RSV epitopes using other display systems (24) (25) (26) . It is also worth noting that, given their structural similarity to T6SS sheaths (8, 9) , the sheath proteins of bacteriophage contractile tails could also be used to produce heterologous sheaths for such sequential antigen boost applications. It remains to be determined whether different VipA/B pairs affect the folding of different protein antigens or prevent degradation of unstable or weak immunogens.
T6SS can also be modified to carry other functional moieties. We used sortase to covalently attach protein antigens (i.e., sfGFP, mCherry, and fHbp) to the surface of preassembled, purified VipA/B sheaths in vitro under native conditions. Other groups have exploited sortase in vitro to label proteins with chemical moieties, such as fluorescent probes (27, 28) , lipids (29) , sugars (30) , and proteins (31) . Sortase may be applied to decorate sheaths with appropriate chemical ligands or adhesins that might give sheaths binding activity for particular target cells, Total mouse IgG ELISA titers are reported as absorbency units at OD 405 for the same serum dilution 1:32,000. **P value < 0.01; ***P value < 0.001; ns, not statistically significant. (B) Mice sera were used in a serum bactericidal assay (SBA) using rabbit complement serum and N. meningitidis strain NZ98/ 254. SBA data are reported as the percentage of bacterial survival (cfu/mL after 60 min of incubation/cfu/mL at time 0) for each serum dilution tested. Pooled sera for each group were used. The horizontal line represents the SBA titer as the reciprocal of serum dilution resulting in a 50% decrease in bacterial cfu/mL at the end of the assay compared with control cfu/mL at time 0. sfGFP sheaths (VipA/B/A-sfGFP) were used as negative controls. Titer = 16 is the limit of detection of the assay. such as APC or tumor cells. In this case, the desired functional domains can be expressed in different cell lines than the one expressing sheaths (e.g., in eukaryotic cells) and subsequently ligated to the surface of sheaths. It is predicted that fusion of sheaths with cell-penetrating peptides (32, 33) will increase the endocytic uptake of sheath particles and facilitate their endosome escape, as proposed for TAT-peptides conjugated to albumin-based lyophilisomes (34). If such an approach can deliver sheaths to the cytosol of APCs, it might be possible to decorate sheaths with epitopes for processing and presentation by the class I MHC pathway, or with enzymes that can synthesize adjuvant molecules (e.g., DncV-related enzymes that could synthesize cyclic di-nucleotides within target cells) (35, 36) . This approach would increase the potential of the T6SS sheath delivery system to induce a cytotoxic T-cell-mediated immune response.
Future experiments will be required to optimize and control the process of antigen exposure on sheaths to consistently generate uniform particles. Nevertheless, the versatility of the T6SS sheathbased delivery system may provide for a broad array of applications and advantages that are difficult to achieve using other described nanoparticle systems available up to now (13) .
Materials and Methods
Expression and Purification of Recombinant Proteins. V. cholerae 2740-80 ΔclpVΔflgGΔvipA and E. coli BL21-DE3 Gold strains were used to coexpress VipA, VipB, and VipA-antigen fusion proteins with the Duet Expression System. Plasmids and primers used for cloning strategies are listed in Tables  S1 and S2 . Sheath-like structures were purified from V. cholerae and E. coli host strains using a two-step purification method: (i) ultraspeed centrifugation of bacterial cell lysates to concentrate the sample and remove not assembled soluble proteins; and (ii) Ni-affinity chromatography purification to purify sheaths carrying VipAhis.
Sheath Characterization. For negative staining electron microscopy, samples were loaded on grids, stained with 0.75% (wt/vol) uranyl formate, and imaged with a transmission electron microscope. For immunogold staining, grids were exposed to mouse primary antibody against the exposed antigen and rabbit anti-mouse bridging antibody, followed by protein A-gold particles. To test sheath uptake by phagocytic cells, RAW 264.7 macrophages were incubated with sfGFP sheaths, and, after 6 or 20 h of incubation, cells were collected and analyzed by flow cytometry to quantify GFP-positive cells. Alternatively, after incubation, cells were stained and imaged by confocal microscopy.
Immunization Experiments and Serology Analysis. The methods for animal experimentation were approved by the Harvard and Boston University Medical Center Institutional Care and Use Committees. Groups of five BALB/c mice were immunized three times intraperitoneally with 20 μg of sheath preparations, with or without alum. Other groups were immunized with 5 μg of recombinant sfGFP, mCherry, or fHbp. An ELISA was designed to measure mouse IgG1, IgG2a, IgG2b, and IgG3 antibodies specific for each exposed antigen, and V. cholerae VipA and VipB, used as scaffold for sheath assembly. Serum bactericidal activity against an N. meningitidis strain was evaluated as previously described (37) .
SrtA Sortase Reaction. VipA/B sheaths, containing an SrtA recognition motif (LPETGG), were incubated with a 10-fold excess of Gly 5 -sfGFP, Gly 5 -mCherry, or Gly 5 -fHbp in a sortase reaction buffer, supplemented with SrtA enzyme. Samples were analyzed by SDS/PAGE and Western blot.
Further details for all of the experimental protocols are provided in SI Materials and Methods.
